Board of Directors

Michael Lewis


Michael Lewis, is Joint Director for the NIHR i4i and SBRi Healthcare programmes as well as being Professor of Life Science Innovation at the University of Birmingham.

Michael has had an extensive industrial background in life sciences and digital innovation in healthcare having previously held senior roles at Align Technology (Amsterdam), Boston Scientific (Paris), C.R. Bard (New Jersey), Sybron (Switzerland) and Becton Dickinson (UK) and was President of Gambro (Sweden) in the £3bn public to private buyout.  Michael has worked for numerous private equity and venture capital organisations and has a deal sheet valued at over $5bn including IPOs in London and New York.

His industry experience covers pharma, biotech, digital, dental, devices, clinical trials and diagnostics. Currently, he is Chair of 3 life science companies all with a real emphasis on citizen focused, data and outcomes driven healthcare. He also sits on the Board of SNOMED, the global medical coding standardisation system, the Executive Board of Birmingham Health Partners and is a special advisor for NHSX.

At the University he lectures on innovation in life sciences and how this aligns with the United Nations 17 Sustainable Development goals and the circular economy. He is also closely involved with delivering the new Birmingham Health Innovation campus, a £210m life science park under construction between the University of Birmingham and University Hospitals Birmingham.

Charles Woler(MD, PhD)

Non-Executive Director

Charles Woler has spent the last 30 years in the healthcare industry, both in large multinational pharmaceutical companies and smaller, earlier stage companies.

He currently holds non-executive Chairman and non-executive Director positions in Europe and the U.S..

Previously Charles was Chairman and CEO of Roche France, Chairman of SmithKline Beecham’s European pharmaceutical business (UK), CEO of Cadus Pharmaceuticals (U.S.) and CEO of Biomnis (France).

William Ringo(MBA)

Board Advisor

Bill is an eminent pharma veteran with nearly 30 years experience of public markets, M&A, product commercialisation, and financial institutions.

He is currently Chairman of Assembly Biosciences Inc., and a director of Sangamo Therapeutics Inc., Immune Design Corp., Dermira Inc., and Five Prime Therapeutics Inc..

Previous roles include Chairman, CEO and President of NASDAQ-listed InterMune, Inc; SVP of Strategy and Business Development at Pfizer, Inc.; President and CEO of NASDAQ-listed Abgenix, Inc. Bill was also a member of Eli Lilly and Company’s operating committee.